Salt form selection and characterization of LY333531 mesylate monohydrate

International Journal of Pharmaceutics

Volumn 198, Issue 2, 2000, Pages 239-247

  Engel, Gary L ^a   Farid, Nagy A ^a   Faul, Margaret M ^a   Richardson, Lori A ^a   Winneroski, Leonard L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Anhydrate; Bioavailability; Hydrochloride salt; LY333531; Mesylate salt; Monohydrate; Pharmaceutical salt form; Protein kinase C( ) inhibitor; Solubility

Indexed keywords

ACETIC ACID; CHLORIDE; MESYLIC ACID; PHOSPHATE; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; SUCCINIC ACID; SULFATE; TARTARIC ACID; WATER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DOG; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG PURITY; DRUG SOLUBILITY; DRUG STABILITY; FILTRATION; HYDRATION; MALE; MICROSCOPY; NONHUMAN; PHYSICAL CHEMISTRY; POWDER; PRIORITY JOURNAL; SCREENING; TECHNIQUE; THERMOGRAVIMETRY; WETTABILITY; X RAY DIFFRACTION;

ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; DRUG STABILITY; ENZYME INHIBITORS; INDOLES; MALEIMIDES; PROTEIN KINASE C; SOLUBILITY;

EID: 0034607382     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(00)00350-1     Document Type: Article

References (11)

1. Amidon G.L., Lennernas H., Shah V.P., Crison J.R. A theroretical basis for a biopharmaceutical drug classifcation: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:1995;413-420.
2. Berge S.M., Bighley L.D., Monkhouse D.C. Pharmaceutical salts. J. Pharm. Sci. 66:1977;1-19.
3. Bighley, L.D., Berge, S.M., Monkhouse, D.C., 1996. Preservation of pharmaceutical products to salt forms of drugs and absorption. In: Swarbrick, J., Boylan, J.C. (Ed.), Encyclopedia of Pharmaceutical Technology 13. Marcel Dekker, New York, pp. 453-499.
4. β inhibitor. Science. 272:1996;728-731.
5. Jamuludin A., Mohamad M., Navartnam V., Selliah K., Tan S.C., Wernsdorfer W.H. Relative bioavailability of the hydrochloride, sulfate, and ethyl carbonate salts of quinine. Br. J. Clin. Pharm. 25:1988;261-263.
6. β). J. Med. Chem. 39, 2664-2671.
7. Lin S.L., Lachman L., Schwartz C.J., Huebner C.F. Preformulation investigation I: relation of salt forms and biological activity of an experimental antihypertensive. J. Pharm. Sci. 61:1972;1418-1422.
8. Miyazaki S., Oshiba M., Nadai T. Precaution on use of hydrochloride salts in pharmaceutical formulations. J. Pharm. Sci. 70:1981;594-595.
9. Morris K.R., Fakes M.G., Thakur A.B., Newman A.W., Singh A.K., Venit J.J. An integrated approach to the selection of optimal salt form for a new drug candidate. Int. J. Pharm. 105:1994;209-217.
10. Thomas E., Rubino J. Solubility, melting point and salting-out relationships in a group of secondary amine hydrochlorides. Int. J. Pharm. 130:1996;179-183.
11. Walmsley L.M., Taylor T., Wilkinson P.A., Brodie R.R., Chasseaud L.F., Alun-Jones V. Plasma concentrations and relative bioavailability of naftidrofuryl from different salt forms. Biopharm. Drug Dispos. 7:1986;327-334.